The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade

Antoni Ribas; Paul C Tumeh

doi:10.1158/1078-0432.CCR-14-0933

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade

Clin Cancer Res. 2014 Oct 1;20(19):4982-4. doi: 10.1158/1078-0432.CCR-14-0933. Epub 2014 Jun 26.

Authors

Antoni Ribas¹, Paul C Tumeh²

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. Department of Surgery, University of California Los Angeles, Los Angeles, California. Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California. Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California. aribas@mednet.ucla.edu.
² Division of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California.

Abstract

It is conceivable that, in the near future, an assay that defines the likelihood of a patient with advanced cancer to respond to immunotherapy based on PD1/L1 blockade will be the initial decision point to select the treatment of patients with any cancer type.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
B7-H1 Antigen / antagonists & inhibitors
Humans
Molecular Targeted Therapy
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / metabolism
Patient Selection
Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

Antineoplastic Agents
B7-H1 Antigen
Programmed Cell Death 1 Receptor

Abstract

Publication types

MeSH terms

Substances

Grants and funding